143 related articles for article (PubMed ID: 386792)
21. Use of 1,25(OH)2-vitamin D3 to separate 'types' on renal osteodystrophy.
Coburn JW; Brickman AS; Sherrard DJ; Singer FR; Wong EG; Baylink DJ; Norman AW
Proc Eur Dial Transplant Assoc; 1977; 14():442-50. PubMed ID: 600961
[TBL] [Abstract][Full Text] [Related]
22. 1,25-dihydroxycholecalciferol in hypophosphataemic osteomalacia presenting in adults.
Offermann G; Delling G; Haussler MR
Acta Endocrinol (Copenh); 1978 Jun; 88(2):408-16. PubMed ID: 580838
[TBL] [Abstract][Full Text] [Related]
23. Biochemical and histological effects of 1,25 dihydroxycholecalciferol (1,25-DHCC) in the osteomalacia of chronic and failure.
Eastwood JB; Phillips ME; de Wardener HE; Bordier J; Marie P; Arnaud CD; Norman AW
J Urol Nephrol (Paris); 1974 Dec; 80(12):984-5. PubMed ID: 4617780
[No Abstract] [Full Text] [Related]
24. Treatment of hemodialysis bone disease with 24,25-(OH)2D3 and 1,25-(OH)2D3 alone or in combination.
Dunstan CR; Hills E; Norman AW; Bishop JE; Mayer E; Wong SY; Eade Y; Johnson JR; George CR; Collett P
Miner Electrolyte Metab; 1985; 11(6):358-68. PubMed ID: 3877862
[TBL] [Abstract][Full Text] [Related]
25. 1,25-dihydroxycholecalciferol in renal osteodystrophy. Epiphysiolysis--anticonvulsant therapy.
Pierides AM; Ellis HA; Dellagrammatikas H; Scott JE; Norman AW
Arch Dis Child; 1977 Jun; 52(6):464-72. PubMed ID: 879832
[TBL] [Abstract][Full Text] [Related]
26. Spontaneous hypercalcemia in patients undergoing dialysis. Etiologic and therapeutic considerations.
Piraino BM; Rault R; Greenberg A; Dominguez JH; Wallia R; Houck P; Segre GV; Chen T; Foti FM; Puschett JB
Am J Med; 1986 Apr; 80(4):607-15. PubMed ID: 3963041
[TBL] [Abstract][Full Text] [Related]
27. Treatment of renal osteodystrophy with 1,25-dihydroxycholecalciferol.
Velentzas C; Oreopoulos DG; Pierratos A; Meema HE; Rabinovich S; Meindok H; Husdan H; Murray TM; Ogilvie R; Katirtzoglou A
Can Med Assoc J; 1981 Mar; 124(5):577-83. PubMed ID: 6894103
[TBL] [Abstract][Full Text] [Related]
28. The response to 1,25-dihydroxycholecalciferol and to dihydrotachysterol in adult-onset hypophosphataemic osteomalacia.
Ahmed KY; Varghese Z; Moorhead JF; Wills MR
Clin Chim Acta; 1979 Sep; 97(1):33-7. PubMed ID: 315284
[TBL] [Abstract][Full Text] [Related]
29. Comparison of 1,25(OH)2D3 and 24,25(OH)2D3 in the long-term treatment of renal osteodystrophy.
Muirhead N; Catto GR; Edward N; Fraser RA; O'Riordan JL; Papapoulos SE; Adami S
Proc Eur Dial Transplant Assoc; 1980; 17():543-7. PubMed ID: 6972529
[TBL] [Abstract][Full Text] [Related]
30. Iliac bone marrow mast cells in relation to the renal osteodystrophy of patients treated by haemodialysis.
Ellis HA; Peart KM
J Clin Pathol; 1976 Jun; 29(6):502-16. PubMed ID: 939806
[TBL] [Abstract][Full Text] [Related]
31. The effect of hemodialysis, vitamin D metabolites and renal transplantation on the skeletal demineralization associated with renal osteodystrophy: a computerized histomorphometric analysis.
Main J; Velasco N; Catto GR; Fraser RA; Edward N; Adami S; O'Riordan JL
Clin Nephrol; 1986 Dec; 26(6):279-87. PubMed ID: 3542321
[TBL] [Abstract][Full Text] [Related]
32. Vitamin D metabolites and bone mineralization in man.
Bordier P; Rasmussen H; Marie P; Miravet L; Gueris J; Ryckwaert A
J Clin Endocrinol Metab; 1978 Feb; 46(2):284-94. PubMed ID: 750606
[TBL] [Abstract][Full Text] [Related]
33. Effects of 25-hydroxycholecalciferol on bone lesions of children with terminal renal failure.
Witmer G; Margolis A; Fontaine O; Fritsch J; Lenoir G; Broyer M; Balsan S
Kidney Int; 1976 Nov; 10(5):395-408. PubMed ID: 794558
[TBL] [Abstract][Full Text] [Related]
34. The clinical spectrum of renal osteodystrophy in 57 chronic hemodialysis patients: a correlation between biochemical parameters and bone pathology findings.
Chazan JA; Libbey NP; London MR; Pono L; Abuelo JG
Clin Nephrol; 1991 Feb; 35(2):78-85. PubMed ID: 2019018
[TBL] [Abstract][Full Text] [Related]
35. Vitamin-D-resistant osteomalacia in hemodialysis patients lacking secondary hyperparathyroidism.
Hodsman AB; Sherrard DJ; Wong EG; Brickman AS; Lee DB; Alfrey AC; Singer FR; Norman AW; Coburn JW
Ann Intern Med; 1981 May; 94(5):629-37. PubMed ID: 6894520
[TBL] [Abstract][Full Text] [Related]
36. [Effect of 1,25-dihydroxycholecalciferol in renal osteopathy].
Reutter FW; Sieber R; Olah AJ; Dambacher MA
Schweiz Med Wochenschr; 1979 Dec; 109(47):1880-3. PubMed ID: 531567
[TBL] [Abstract][Full Text] [Related]
37. [Evolving aspects of uremic osteodystrophy in the dialized patient].
Zucchelli P; Fusaroli M; Fabbri L; Catizone L; Pavlica P; Viglietta G; Casanova S
J Urol Nephrol (Paris); 1976; 82(4-5):325-8. PubMed ID: 940176
[No Abstract] [Full Text] [Related]
38. Decreased renal function in association with administration of 1,25-dihydroxyvitamin D3 to patients with stable, advanced renal failure.
Christiansen C; Røodbro P; Christensen MS; Naestoft J; Hartnack B; Transbøol I
Contrib Nephrol; 1980; 18():139-46. PubMed ID: 6243527
[TBL] [Abstract][Full Text] [Related]
39. Use of 1,25(OH)2-vitamin D3 in prevention of renal osteodystrophy: preliminary observations.
Baker LR; Muir JW; Cattell WR; Tucker KA; Sharman VL; Goodwin FJ; Marsh FP; Hately W; Morgan AG; de Saintonge DM
Contrib Nephrol; 1980; 18():147-51. PubMed ID: 7353373
[TBL] [Abstract][Full Text] [Related]
40. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
